Voluntary drug pricing agreements between the White House and midsize biotechnology companies are unlikely to change what most Americans pay for their prescriptions, at least in the near term, analysts say. The agreements follow a most-favored-nation framework: the United States would pay prices for drugs comparable to what peer nations pay. The deals apply chiefly to Medicaid, which already receives the lowest prices of any U.S. payer by law, while exempting companies from mandatory Medicare price reductions.
President Trump announced the agreements Monday. He has pursued drug pricing as a political priority and believes the issue will help Republicans in the midterm elections. The most-favored-nation concept is his administration's answer to a persistent complaint: that Americans pay far more for the same medicines than patients in other wealthy countries.
Why the Medicaid focus limits the impact
Medicaid is the joint federal-state insurance program covering low-income Americans, and it already operates under a legal requirement to receive the lowest drug prices of any payer in the country. That is not a negotiated discount. It is a statutory mandate. Applying a most-favored-nation standard to a program already required to get the deepest discounts changes very little about the pricing floor.
What the deals exempt
The Medicare carve-out is the more telling detail. Medicare covers older Americans and people with certain disabilities, and it accounts for a significant share of total U.S. prescription drug spending. Mandatory price reductions there would put direct financial pressure on pharmaceutical companies and deliver real savings to enrollees. The new agreements exempt participating companies from those mandatory cuts.
The voluntary structure of the deals matters too. No midsize biotechnology company is required to participate. Analysts say the combination of optional participation, a Medicaid focus, and an explicit Medicare exemption narrows the real-world effect of the announcement considerably. The largest unresolved question remains mandatory reductions in Medicare.